Livanova Plc · NASDAQ:LIVN
Livanova — Investor Day (September 2017)
17 slides from Livanova's investor day presentation, Sep 14, 2017
Slide 1: LivaNova Investor Day: Neuromodulation
NEUROMODULATION LivaNova Investor Day Jason Richey General Manager, Neuromodulation & President, North America September 14, 2017
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this presentation, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 19
Slide 3: We are the market leader in Vagus Nerve Stimulation (VNS) Therapy
We are the market leader in Vagus Nerve Stimulation (VNS) Therapy® EPILEPSY DEPRESSION Significant growth opportunity Unmet global need CUSTOMERS DISEASE STATE MARKET Neurologists Drug-resistant epilepsy Large underpenetrated Epileptologists (DRE) markets with opportunity Psychiatrists Treatment-res
Slide 4: Neuromodulation is a large and growing market
Neuromodulation is a large and growing market Neuromodulation (NM) Market Technology Growing number Patient awareness 11.2% $6.2B advancements of indications and physician CAGR acceptance Epilepsy • Miniaturization • Epilepsy • Patients largely NM market • Battery longevity • Chronic pain influence
Slide 5: Epilepsy
EPILEPSY 5
Slide 6: ~35% of patients need treatment beyond medication
~35% of patients need treatment beyond medication Significant growth opportunity remains Epilepsy patients ~10M Drug resistant ~3M Referral Gap Evaluated at EMU ~300K / yr Surgery/Other ~7K / yr Treatment Gap Treated VNS ~8K / yr Source: Prevalence data and approximations based on CDC; EMU = Epileps
Slide 7: Growing through innovation and patient awareness
Growing through innovation and patient awareness MRI (U.S. and OUS) and Remove barriers pediatric labeling expansions (U.S.) Maintain new product cadence Innovation every 12-24 months International growth Strategic targeting of key markets opportunities Direct-to-consumer marketing Patient awareness
Slide 8: Unlocking potential via labeling expansions
Unlocking potential via labeling expansions FDA expanded VNS Therapy access to patients as young as age 4 (2017) OUS CE Mark approval with no age restrictions (1994) Pediatric Clinical data proves early adjunctive use yields better results Patients having seizures for <10 years respond better to VNS
Slide 9: Developing customer-centric innovation
Developing customer-centric innovation Providing ease of use, better patient care, cost effectiveness SenTivaTM innovations Future generations • Senses bradycardia and • Auto gain control – tachycardia minimal device positioning by physician • Monitors patient sleeping position • Microburst – new va
Slide 10: Targeting international markets
Targeting international markets More than 100K global patients treated ~15% • Focused team with 30% regional marketing OUS • Key markets: UK, Germany, Nordics, High-single to France, Japan low-double- digit growth with M&A • Increase sales force 70% U.S. • Enhance R&D teams ~85% 2017 2022 Source: Li
Slide 11: Clinical studies to further support adoption
Clinical studies to further support adoption Our customers rely on data PATIENT REGISTRY EARLY ADJUNCTIVE USE STUDY • Goes live in parallel with SenTiva launch • Prospective multi-center study • Tracks seizure activity and overall patient • Patients 4+ years quality of life • VNS as adjunctive thera
Slide 12: Universal platform: foundation for additional indications
Universal platform: foundation for additional indications Psychiatric Disorders VNS for Chronic VNS for Heart Failure Epilepsy Patient Data and analytics Movement Universal Rheumatoid clinician Disorders Platform Arthritis and diagnostic processing tools Genitourinary Obstructive Disorders Sleep Apn
Slide 13: Depression
DEPRESSION 13
Slide 14: Depression affects patients in the prime of their life and burdens families and society
Depression affects patients in the prime of their life and burdens families and society • 300M+ patients globally • Median age of onset: 25 years Depression • Fewer than half of patients receive treatment • Leading cause of disability and major burden • ~10-30% of patients with depression Treatment-
Slide 15: Exploring options for LivaNova's TRD treatment
Exploring options for LivaNova’s TRD treatment Received CE Mark in 2001 Received FDA approval in 2005 Currently have 4,000 devices implanted over ~18-month period Started pilot trial in Germany in 1Q17 Planning scaled launch in other European countries where we have approval and reimbursement Ongoin
Slide 16: Summary: a pioneer in Neuromodulation with robust growth opportunities
Summary: a pioneer in Neuromodulation with robust growth opportunities • Strong core growth driven by consistent product innovation • Label expansion increases patient pool Epilepsy • International expansion opportunities • Inorganic opportunities drive high-single- to low-double-digit growth trajec
Slide 17: LivaNova
LivaNova = ivaNova Health innovation that matters 17